FRM
BCAX icon

Fox Run Management’s Bicara Therapeutics BCAX Stock Holding History

Fox Run Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$264K Buy
+14,205
New +$356K 0.03% 792

Other funds holding BCAX

SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Red Tree Management
Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JHC
Jones Hill Capital New York $589M AUM
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Fox Run Management's BCAX Position: Q3 2026 in Review

Fox Run Management opened a new position in Bicara Therapeutics (BCAX) in Q3 2026: 14,205 shares worth $264K. The stake represents 0.03% of the portfolio and ranks #792 among its holdings.

114 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

  • Fox Run Management held 14,205 shares of Bicara Therapeutics worth $264K as of Q3 2026.
  • Bicara Therapeutics was a new Fox Run Management position in Q3 2026.
  • Bicara Therapeutics made up 0.03% of Fox Run Management's portfolio in Q3 2026, its #792 holding.
  • 114 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on Fox Run Management's 13F filing for Q3 2026, filed 12 Nov 2026.